Companies › Unravel Biosciences
1 active drug program in 24 registered trials: 18 Phase 1, 6 Phase 2; Hematology, Immunology, Oncology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vorinostat Histone deacetylase 1 inhibitor; Histone deacetylase 3 inhibitor; Histone deacetylase 6 inhibitor | HDAC (class I/II) | Phase 1 | Rett Syndrome; Pitt Hopkins Syndrome; Castration-Resistant Prostate Carcinoma; Metastatic Uveal Melanoma … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03842696 | Vorinostat | Phase 1 | Hematologic Diseases | Oncology | Jul 2025 |
| NCT01087554 | Vorinostat | Phase 1 | Advanced Cancer | Oncology | Aug 2026 |
| NCT03742245 | Vorinostat | Phase 1 | Breast Cancer Metastatic | Oncology | Dec 2026 |
| NCT06145633 | Vorinostat | Phase 2 | Castration-Resistant Prostate Carcinoma | Oncology | Dec 2026 |
| NCT07150013 | Vorinostat | Phase 1 | Rett Syndrome | Psychiatry | Dec 2026 |
| NCT07150026 | Vorinostat | Phase 1 | Pitt Hopkins Syndrome | Other | Dec 2026 |
| NCT01587352 | Vorinostat | Phase 2 | Metastatic Uveal Melanoma | Oncology | Dec 2026 |
| NCT00392353 | Vorinostat | Phase 1 | Acute Erythroid Leukemia | Hematology | Dec 2026 |
| NCT04308330 | Vorinostat | Phase 1 | Ewing Sarcoma | Oncology | Dec 2026 |
| NCT05317403 | Vorinostat | Phase 1 | Acute Myeloid Leukemia, in Relapse | Oncology | Jan 2027 |
| NCT00616967 | Vorinostat | Phase 2 | Breast Cancer | Oncology | Feb 2027 |
| NCT00972478 | Vorinostat | Phase 1 | Ann Arbor Stage II Non-Hodgkin Lymphoma | Oncology | Mar 2027 |
| NCT01522976 | Vorinostat | Phase 2 | Chronic Myelomonocytic Leukemia | Hematology | Mar 2027 |
| NCT00336063 | Vorinostat | Phase 1 | Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Oncology | Mar 2027 |
| NCT01281176 | Vorinostat | Phase 1 | Adult Solid Neoplasm | Oncology | Apr 2027 |
| NCT00268385 | Vorinostat | Phase 1 | Adult Anaplastic Astrocytoma | Oncology | Apr 2027 |
| NCT03150329 | Vorinostat | Phase 1 | Grade 3b Follicular Lymphoma | Oncology | Jun 2027 |
| NCT01297764 | Vorinostat | Phase 1 | Multiple Myeloma | Oncology | Jun 2027 |
| NCT02638090 | Vorinostat | Phase 1 | Lung Cancer | Oncology | Jun 2027 |
| NCT03843528 | Vorinostat | Phase 1 | Acute Myeloid Leukemia | Oncology | Jul 2027 |
| NCT06995521 | Vorinostat | Phase 2 | GVHD | Immunology | Sep 2028 |
| NCT02559778 | Vorinostat | Phase 2 | Neuroblastoma | Oncology | Sep 2030 |
| NCT02553460 | Vorinostat | Phase 1 | Acute Lymphoblastic Leukemia | Oncology | Oct 2031 |
| NCT03167437 | Vorinostat | Phase 1 | Crohn's Disease | Immunology | Jun 2035 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.